Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/29241357
Conclusion of this study
These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD's effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study